)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Syntara
Syntara (SNT) investor relations material
Syntara Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary29 Oct, 2026
Executive summary
Phase 2 SNT-4728 results showed reduced putamen inflammation and statistically significant improvement in clinician-assessed motor signs 12 weeks after treatment ended.
AZALOX advanced to its final Phase 1b dose cohort; a $4.7 million R&D tax incentive supported development programs, and quarter-end cash was $14.1 million.
Financial highlights
Cash and cash equivalents were $14.060 million at 30 September 2026, versus $13.562 million at 30 June 2026; net operating cash inflow was $649,000.
Operating cash outflows included $1.989 million for R&D, $1.787 million for staff and $597,000 for administration and corporate costs; R&D and staff represented 89% of net operating cash outflows.
Outlook and guidance
AZALOX is expected to progress to a Phase 2 component evaluating the selected amsulostat dose in ~30 patients, subject to completion and review of final-cohort safety data.
SNT-9465 top-line results are expected in Q1 2027; preliminary MESSAGE study results are anticipated in H1 2027.
Further SNT-4728 analyses of digital endpoints and clinical, biological and imaging biomarkers remain outstanding; additional studies are needed to establish clinical benefit and any effect on disease progression.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Syntara
- Amsulostat leads a three-asset pipeline with near-term clinical catalysts.SNT
Investor presentation - Net loss widened to $9.0 million as revenue fell and new equity raised $8.8 million.SNTH2 2026
- FDA-backed late-stage trials and strong cash position set up major clinical catalysts in H2 2026.SNTQ4 2026 TU
- Shareholders voted on two share placement resolutions, with results to be announced later today.SNTEGM 2026
- Phase II/2a trial of SNT-4728 targets neuroinflammation in iRBD, results due by June or 2026.SNTStatus update
- FDA supports Phase 2b for amsulostat; cash runway extended after A$8m placement.SNTQ3 2026 TU
- FDA backs Phase 2b amsulostat trial; funding secured for key 2026 milestones.SNTInvestor update
- 73% achieved TSS50 and 44% SVR25 with strong tolerability and ongoing development plans.SNTStudy Update
- Phase 2 myelofibrosis trial fully recruited; A$5m raised; interim data due December 2024.SNTQ1 2025 TU
Next Syntara earnings date
AGM 202618 Nov, 2026
Syntara
Next Syntara earnings date
AGM 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)